KR100617485B1 - 파필로마바이러스 감염의 치료 - Google Patents
파필로마바이러스 감염의 치료 Download PDFInfo
- Publication number
- KR100617485B1 KR100617485B1 KR1020017007244A KR20017007244A KR100617485B1 KR 100617485 B1 KR100617485 B1 KR 100617485B1 KR 1020017007244 A KR1020017007244 A KR 1020017007244A KR 20017007244 A KR20017007244 A KR 20017007244A KR 100617485 B1 KR100617485 B1 KR 100617485B1
- Authority
- KR
- South Korea
- Prior art keywords
- vlps
- therapeutic vaccine
- infection
- hpv
- hpv11
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Description
Claims (31)
- PV L1 VLPs(파필로마 바이러스 L1 바이러스 유사입자)와 PV L1/L2 VLPs(파필로마 바이러스 L1/L2 바이러스 유사입자)로 구성된 그룹에서 선택된 PV VLPs(파필로마 바이러스 유사입자)를 포함하고 PV E 단백질(파필로마 바이러스 E 단백질)을 배제하는 것을 특징으로 하는, 현존하는 HPV(인간 파필로마바이러스) 감염 치료용 치료 백신.
- 제 1 항에 있어서, 상기 HPV 감염이 상피 병변의 존재를 특징으로 하는 치료 백신.
- 제 2 항에 있어서, 상기 상피 병변이 손바닥 사마귀, 발바닥 사마귀, 항문-생식기 사마귀, 피부와 점막 표면의 평편 및 평면 사마귀, 자궁경부상피내종양(CIN), 말 유육종증, 및 복제 또는 식물성 파필로마 바이러스 감염으로 구성된 그룹에서 선택되는 것을 특징으로 하는 치료 백신.
- 제 3 항에 있어서, 상기 파필로마 바이러스 감염이 HPV 6 또는 HPV 11에 의해 유발된 생식기 사마귀인 것을 특징으로 하는 치료 백신.
- 삭제
- 제 1 항에 있어서, PV L1 VLPs를 포함하는 것을 특징으로 하는 치료 백신.
- 제 1 항에 있어서, PV L1 유전자를 적절한 벡터에 클로닝하고 그 벡터에 의해 형질전환된 진핵세포에서 L1에 대한 해당하는 형태적 코딩 시퀀스를 발현함으로써, 상기 VLPs를 생산하는 것을 특징으로 하는 치료 백신.
- 제 1 항에 있어서, PV L1 과 PV L2 유전자를 적절한 벡터에 클로닝하고 그 벡터에 의해 형질전환된 진핵세포에서 L1과 L2에 대한 해당하는 형태적 코딩 시퀀스를 발현함으로써, 상기 VLPs를 생산하는 것을 특징으로 하는 치료 백신.
- 제 7 항 또는 제 8 항에 있어서, 상기 L1 혹은 L1 과 L2 유전자를 측면에 위치하는 바큘로 바이러스 시퀀스를 포함하는 발현 벡터에 삽입시켜 유전자 구조물을 형성시키고 그 결과 생성된 재조합 DNA를 허용 세포주에 야생형 바큘로바이러스 DNA와 함께 트랜스펙션 시키는 것을 특징으로 하는 치료 백신.
- 제 9 항에 있어서, 상기 세포주가 Sf9 곤충 세포이고 상기 발현 벡터가 바큘로바이러스 발현 벡터인 것을 특징으로 하는 치료 백신.
- 제 9 항에 있어서, 상기 세포주가 원핵세포인 것을 특징으로 하는 치료 백신.
- 제 1 항에 있어서, 상기 환자에게 투여되는 PV VLP의 일회 투여량이 0.5-20μg인 것을 특징으로 하는 치료 백신.
- 제 12 항에 있어서, 상기 일회 투여량이 1-10μg인 것을 특징으로 하는 치료 백신.
- 제 1 항에 있어서, 상기 PV VLPs가 보조제를 배제하는 것을 특징으로 하는 치료백신.
- 제 1 항에 있어서, PV VLPs의 투약은 8-16주의 기간에 걸쳐 3-6회 수행하는 것을 특징으로 하는 치료 백신.
- 제 1 항에 있어서, PV VLPs의 투약은 2-4주의 기간에 걸쳐 3-6회 수행하는 것을 특징으로 하는 치료 백신.
- HPV6 L1 VLPs와 HPV6 L1/L2 VLPs로 구성된 그룹에서 선택된 HPV6 VLPs를 포함하고 HPV E 단백질을 배제하는 것을 특징으로 하는, 현존하는 HPV11 감염 치료용 치료 백신.
- 제 17 항에 있어서, HPV6b VLPs를 포함하는 것을 특징으로 하는 치료 백신.
- 제 17 항에 있어서, 상기 HPV6 VLPs의 일회 투여량이 0.5-20μg인 것을 특징으로 하는 치료 백신.
- 제 19 항에 있어서, 상기 HPV6 VLPs의 일회 투여량이 1-10μg인 것을 특징으로 하는 치료 백신.
- 제 17 항에 있어서, 상기 HPV6 VLPs의 투약은 8-16 주에 걸쳐 3-6회 수행하는 것을 특징으로 하는 치료 백신.
- 제 17 항에 있어서, 상기 HPV6 VLPs의 투약은 2-4 주에 걸쳐 3-6회 수행하는 것을 특징으로 하는 치료 백신.
- HPV11 L1 VLPs와 HPV11 L1/L2 VLPs로 구성된 그룹에서 선택된 HPV11 VLPs를 포함하고 HPV E 단백질을 배제하는 것을 특징으로 하는, 현존하는 HPV6 감염 치료용 치료 백신.
- 제 23 항에 있어서, 상기 HPV11 VLPs의 일회 투여량이 0.5-20μg 인 것을 특징으로 하는 치료 백신.
- 제 24 항에 있어서, 상기 HPV11 VLPs의 일회 투여량이 1-10μg 인 것을 특징으로 하는 치료 백신.
- 제 23 항에 있어서, 상기 HPV11 VLPs의 투약은 8-16주의 기간에 걸쳐 3-6회 수행하는 것을 특징으로 하는 치료 백신.
- 제 23 항에 있어서, 상기 HPV11 VLPs의 투약은 2-4주의 기간에 걸쳐 3-6회 수행하는 것을 특징으로 하는 치료 백신.
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP7653A AUPP765398A0 (en) | 1998-12-11 | 1998-12-11 | Treatment of papillomavirus infections |
AUPP7653 | 1998-12-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010103711A KR20010103711A (ko) | 2001-11-23 |
KR100617485B1 true KR100617485B1 (ko) | 2006-09-01 |
Family
ID=3811858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017007244A KR100617485B1 (ko) | 1998-12-11 | 1999-12-13 | 파필로마바이러스 감염의 치료 |
Country Status (12)
Country | Link |
---|---|
US (2) | US6867033B1 (ko) |
EP (1) | EP1144005B1 (ko) |
JP (2) | JP5274737B2 (ko) |
KR (1) | KR100617485B1 (ko) |
AT (1) | ATE344053T1 (ko) |
AU (1) | AUPP765398A0 (ko) |
CA (1) | CA2353866C (ko) |
DE (1) | DE69933891T2 (ko) |
DK (1) | DK1144005T3 (ko) |
NZ (1) | NZ512850A (ko) |
WO (1) | WO2000035478A1 (ko) |
ZA (1) | ZA997638B (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE357252T1 (de) * | 1998-10-16 | 2007-04-15 | Glaxosmithkline Biolog Sa | Adjuvanzsysteme und impfstoffe |
AUPP765398A0 (en) | 1998-12-11 | 1999-01-14 | University Of Queensland, The | Treatment of papillomavirus infections |
FR2802426B1 (fr) * | 1999-12-15 | 2004-04-02 | Neovacs | Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires |
AUPR446801A0 (en) | 2001-04-18 | 2001-05-17 | University Of Queensland, The | Novel compositions and uses therefor |
EP1422526A1 (en) * | 2002-10-28 | 2004-05-26 | MTM Laboratories AG | Method for improved diagnosis of dysplasias |
AU2006236905B2 (en) | 2005-04-15 | 2010-06-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
KR20180084139A (ko) | 2015-12-04 | 2018-07-24 | 시아먼 유니버시티 | 11형 인유두종 바이러스 엘1 단백질의 돌연변이체 |
WO2023196884A1 (en) | 2022-04-06 | 2023-10-12 | Juno Therapeutics, Inc. | Detection assay for human papillomavirus (hpv) type 16 (hpv-16) |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE332973T1 (de) | 1991-07-19 | 2006-08-15 | Univ Queensland | Polynukleotidabschnitt des hpv16-genoms |
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
US5888516A (en) * | 1994-05-16 | 1999-03-30 | Merck & Co. Inc. | Recombinant papillomavirus vaccines |
CN1152935A (zh) * | 1994-05-16 | 1997-06-25 | 麦克公司 | 乳头状瘤病毒疫苗 |
WO1996007792A1 (en) * | 1994-09-06 | 1996-03-14 | Scan-Web I/S | A method and a system for manufacturing broad airlaid paper webs containing an absorbing powder |
AR004464A1 (es) | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
US5821087A (en) | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
AU4258297A (en) * | 1996-09-11 | 1998-04-02 | Merck & Co., Inc. | Papillomavirus vaccine formulation |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
EP0957936B1 (en) * | 1996-12-20 | 2006-10-04 | MERCK & CO., INC. | Formulations of recombinant papillomavirus vaccines |
CA2286294A1 (en) * | 1997-04-08 | 1998-10-15 | Merck & Co., Inc. | Stabilized human papillomavirus formulations |
DE19735118C1 (de) * | 1997-08-13 | 1998-08-13 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
US6228368B1 (en) * | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
AUPP765398A0 (en) | 1998-12-11 | 1999-01-14 | University Of Queensland, The | Treatment of papillomavirus infections |
US6436402B1 (en) * | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
-
1998
- 1998-12-11 AU AUPP7653A patent/AUPP765398A0/en not_active Abandoned
-
1999
- 1999-12-13 ZA ZA9907638A patent/ZA997638B/xx unknown
- 1999-12-13 AT AT99966765T patent/ATE344053T1/de active
- 1999-12-13 JP JP2000587797A patent/JP5274737B2/ja not_active Expired - Lifetime
- 1999-12-13 DE DE69933891T patent/DE69933891T2/de not_active Expired - Lifetime
- 1999-12-13 DK DK99966765T patent/DK1144005T3/da active
- 1999-12-13 NZ NZ512850A patent/NZ512850A/xx not_active IP Right Cessation
- 1999-12-13 US US09/868,009 patent/US6867033B1/en not_active Expired - Lifetime
- 1999-12-13 CA CA2353866A patent/CA2353866C/en not_active Expired - Lifetime
- 1999-12-13 EP EP99966765A patent/EP1144005B1/en not_active Expired - Lifetime
- 1999-12-13 KR KR1020017007244A patent/KR100617485B1/ko active IP Right Grant
- 1999-12-13 WO PCT/AU1999/001108 patent/WO2000035478A1/en active IP Right Grant
-
2005
- 2005-03-15 US US11/079,525 patent/US7172870B2/en not_active Expired - Lifetime
-
2010
- 2010-11-25 JP JP2010261979A patent/JP2011037902A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20050244433A1 (en) | 2005-11-03 |
WO2000035478A1 (en) | 2000-06-22 |
JP5274737B2 (ja) | 2013-08-28 |
US6867033B1 (en) | 2005-03-15 |
DE69933891D1 (de) | 2006-12-14 |
ZA997638B (en) | 2000-07-06 |
DE69933891T2 (de) | 2007-06-21 |
EP1144005A4 (en) | 2005-02-09 |
NZ512850A (en) | 2004-01-30 |
AUPP765398A0 (en) | 1999-01-14 |
ATE344053T1 (de) | 2006-11-15 |
CA2353866C (en) | 2013-11-19 |
DK1144005T3 (da) | 2007-03-05 |
US7172870B2 (en) | 2007-02-06 |
JP2002532434A (ja) | 2002-10-02 |
EP1144005B1 (en) | 2006-11-02 |
EP1144005A1 (en) | 2001-10-17 |
JP2011037902A (ja) | 2011-02-24 |
CA2353866A1 (en) | 2000-06-22 |
KR20010103711A (ko) | 2001-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | HPV6b virus like particles are potent immunogens without adjuvant in man | |
Brun et al. | Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy | |
Corona Gutierrez et al. | Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus | |
Petäjä et al. | Long‐term persistence of systemic and mucosal immune response to HPV‐16/18 AS04‐adjuvanted vaccine in preteen/adolescent girls and young women | |
Pinto et al. | Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles | |
US7172870B2 (en) | Treatment of papillomavirus infections | |
JP2004535816A (ja) | Cinを含むhpv関連の前癌性増殖および癌性増殖に関する方法および組成物 | |
JP2016538333A (ja) | ヒトパピローマウイルス治療ワクチン | |
RU2420313C2 (ru) | Вакцина против вирусов папилломы человека hpv 16 и hpv 18 и по меньшей мере еще одного типа hpv, выбранного из hpv 31, 45 или 52 | |
JP4854742B2 (ja) | 抗hpv感染症薬の調製におけるノカルディア・ルブラ細胞壁骨格の使用 | |
US20150098959A1 (en) | Mucosal Immunity-Stimulating Agent, and Oral Pharmaceutical Composition for Treating HPV Infection | |
JP2012102132A (ja) | Hpv16およびhpv18ならびにhpv31、45または52から選ばれる少なくとも1つの別のhpv型に対するワクチン | |
KR20080005585A (ko) | 백신 | |
Foldvari et al. | Recent progress in the application of nanotechnology for prevention and treatment of human papillomavirus infection | |
WO2006004878A9 (en) | Attenuated herpes simplex virus type-2, vectors thereof and immunogenic compositions thereof | |
AU762114B2 (en) | Treatment of papillomavirus infections | |
Sanders et al. | Cross-neutralizing protection of vaginal and oral mucosa from HPV challenge by vaccination in a mouse model | |
CN115605224A (zh) | 同源腺病毒载体的施用 | |
Weissenbacher et al. | Immunology of genital tract infections | |
KR20080005583A (ko) | 백신 | |
Kyuregyan et al. | UNIVERSAL SINGLE-DOSE VACCINATION AGAINST HEPATITIS A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120802 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20130731 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140729 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150730 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160805 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170728 Year of fee payment: 12 |